The purpose of this research study is to see if using a combination of medications will work better than placebo to treat methamphetamine use disorder. The two medications to be tested are bupropion (also called Wellbutrin) and naltrexone (also called Vivitrol).
The purpose of this study is to further refine the NIDA PhAB Phenotype Battery with
specific attention paid to sub-typing participant characteristics in order to create better
treatments for substance users in the future. The goal is for this battery to be efficiently
embedded into future clinical trials.
The purpose of this study is to see if a combined treatment of injectable extended-release naltrexone (XR-NTX; Vivitrol®) and injectable extended-release Buprenorphine (XR-BUP; Sublocade®) are safe and effective for helping people cut down or stop using cocaine.
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate the Pharmacokinetics and Safety of Twice Yearly Long-Acting Subcutaneous Lenacapavir for Pre-Exposure Prophylaxis in People Who Inject Drugs.